EVOLVING SCIENTIFIC AND REGULATORY PERSPECTIVES ON CELL SUBSTRATES FOR VACCINE DEVELOPMENT WORKSHOP 1999
“Every now and then I think we need to remind ourselves that viruses can propagate only in live cells, and this of course holds true for whole viral vaccines. They can only be produced in cells. The choice of suitable cell substrates for the manufacture of viral vaccines has over the years engendered considerable discussion.
The primary focus in these discussions on cell substrates have been safety, in particular the potential safety concerns from residual cellular DNA and from adventitious viral agents. As history has shown, the need for concern about cell substrate issues was real. We have only to think back to the finding of SV40 in polio virus vaccines to realize the extent of the risk that any cell substrate may pose, and there is still great need for concern.”
Opening remarks by Regina Rabinovich,M.D. Institute of Allergy and Infectious Diseases, NIH
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH
INTERNATIONAL ASSOCIATION FOR BIOLOGICALS
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
NATIONAL VACCINE PROGRAM OFFICE
WORLD HEALTH ORGANIZATION
Over a decade ago… but discussions showing concern are still being had. Vaccines are being developed using cancerous dog cells … I hope they know what they are doing…
“Even though several studies have been conducted to assure vaccine developers that PER.C6 cells do not cause cancer and do not contain stray tumor causing viruses, the risk of the cells making their way into the final vaccine products remain.”
Dr Sherri Tenpenny, 2009
n.b. SV40 is an abbreviation for Simian vacuolating virus 40 or Simian virus 40, a polyomavirus that is found in both monkeys and humans. Like other polyomaviruses, SV40 is a DNA virus that has the potential to cause tumors, but most often persists as a latent infection.
Studies show SV40 is not likely to cause cancer in humans, but the most worrying is that these studies were done after the event!
Vaccine shedding is not a myth, but the papers suggest that it is rare and probably not enough to actually cause disease in another person. However, there are many anecdotal stories of measles being contracted from recently boosted children.
At the BSEMconference Dr Andrew Wakefield worryingly offered us further developments to horizontal transmission. That vaccine related measles, like vaccine related Polio when the vaccine was live (thus the change to the inactive), is occurring all over the world. That strains of measles vaccines have been found in un vaccinated monkeys who had associated with vaccinated monkeys.
(I will add that as disease transmission is little understood, along with the possibility that the live vaccine will shed the virus and cause disease, there may be a sympathetic transmission between species also.)
I attended the BSEM conference and heard an amazing presentation on the JVCI. Under the FOI Dr Lucia Tomljenovic obtained meeting notes from our Joint Committee of Vaccines and Immunization from the past 30 years, which appeared to show attempts to protect the vaccine program above safety concerns.
I am sad to admit this may be the case with evidence such as Japan and Canada leading the way to replace the Urabe strain of the mumps in 1988, while the JCVI avoided any statement on the risk of neurological reaction. Finally the lawyers of the vaccine manufacturers advised them to withdraw this vaccine several years later!
From my conversation with Dr David Salisbury of the JCVI, where he told me with pride that only the most safe and pure vaccines were used as placebos in safety trials, I can see that a blind belief in the safety and efficacy of vaccines may be partly to blame for a reluctance for openness and action.
Please email her from the link here if you need
Looking specifically at vaccines, Dr Halverson pointed out that most vaccines were both THelperType 2 inducing and IgE stimulating, thus likely to stimulate allergy in an atopic (allergy prone) subject. Moreover, aluminium, frequently used as an adjuvant (a substance included in the vaccine to increase its potency) is a powerful inducer of IgE.
However, actually catching some of the infections against which we are vaccinating our children appears to reduce their risk of allergy dramatically. Catching measles reduces the risk of asthma by 80% and of allergy in general by 30%; chicken pox, caught under the age of eight, reduces the risk of eczema by 45% and reduces the risk of severe eczema by a dramatic 96%.
The timing of the administration of the vaccine also seems to be important. Children who completed the triple course after 12 months reduced their risk of developing hay fever while if the first vaccine was delayed from two month to five months old, the risk of asthma was reduced by 50%. (Measles killed around 50 UK children per year before the vaccine but asthma kills over 100 children in the UK now…)
Dr Halverson also pointed out that the conclusions drawn from scientific papers were often at odds with their results. For example, is was generally concluded that the MMR vaccine was not a risk factor for asthma and eczema, a conclusion that was in direct contradiction to the results of the research.
From the BSEM study day conference 11.3.11 notes from
|A tablet a day keeps the patient at bay: the health hazards of prevention – vaccinations and pharmacoprophylaxis BSEM conference 11th March 2011|
|‘Do no harm!’, said Dr David Freed, introducing the British Society of Environmental Medicine’s excellent conference which he had also organised, ‘That is the charge put upon doctors when they qualify. But do they?’
Thank you to this site for summarizing the speakers – It saves me writing up my notes
Routine vaccinations – the science – Dr Jayne Donegan.
Vaccines, Atopy and Allergy: Problems and Solutions – Dr Richard Halverson
Public deceit, abuse of power and flawed science; vaccination policy of Joint Committee on Vaccination an Immunisation (JCVI) Dr Lucija Tomljenovic of the University of British Columbia
The ‘Curious Case of the Post Vioxx Statin Trials’
Christina England, adoptive mother of two special needs boys, described the horrifying misdiagnoses of Munchausen’s Syndrome by proxy www.profitableharm.com
Global concerns about HPV Vaccinations www.sanevax.org
Mitochondrial dysfunction in pill mothers and Autisic Spectrum Disorders
Dr Andrew Wakefield www.callous-disregard.com